The Network (ATDN) is a national, not for profit organization that provides case management, treatment and care access education and information, advocacy and counseling, and other services for people with chronic hepatitis, AIDS, and HIV/Hepatitis co-infection. There is no fee, charge or donation required to receive our services. We accept and appreciate donations of any amount, but a contribution is not required to receive our services. Many of our services are provided by volunteers, so please e-mail us first at The Network for help getting drugs or services. Please include your zip code and/or city and state, as well as the drug or treatments or services you need Names and return phone numbers are also very helpful. If you are unable to e-mail us for any reason, our national toll-free number is (800) 734-7104. You can leave a message at extension 16. States are continually being updated with information on HIV and Hepatitis services and treatments through The Access Project. If you'd like to help keep these state resource listings current and inclusive, let us know which state and what resouces. For example, the recently approved drugs Aptivus, Intelence, Isentress, Prezista and Selzentry are on or being added to AIDS Drug Assistance Program and Medicaid formularies (which alredy include drugs like boosted Invirase, Fuzeon, Epzicom, Truvada, Atripla and Reyataz to create effective HIV regimens). Some already make some or all of these treatments, as well as others, to eligible clients. Some states are also adding hepatitis vaccines and Hepatitis B and/or Hepatitis C treatments. Do you provide resource or resources in a state, or make use of them? Are you leading an HIV or Hepatitis or other advocacy effort in your state? We'll list your effort on that state's resources page if you like. Contact The Network by e-mail or fax us with information at (212) 260-8869 (FAX). You can also call us toll-free at PHONE: (800)734-7104, ext. 16. Thank You. |
 People with HIV or HIV/Hepatitis co-infection
who live in the New York City area (all boroughs as well as surrounding areas and parts of New Jersey) can enroll in our no fee, no insurance
required case management
program. News BriefsFDA has granted accelerated approval for a new anti-HIV drug. The drug, Intelence (also known as etravirine or TMC-125) was approved based on two trials conducted mostly in men who had very few HIV treatment options. Over 3000 people have also received the drug through an Expanded Access Program. The links below are for several press releases, including one from the FDA, Tibotec (the makers of the drug), and The Fair Pricing Coalition. The FDA approved label for the drug is included as well.
|